GlassScriptPhysician profile
Pablo R Proano
NPI 1639109036
$111,883.25
in general payments reported to CMS, 2019-2025
30 companies · $5,577 in 2025
The $5,577 reported for 2025 was more than what 95% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43K · 2020: $19K · 2021: $12K · 2022: $13K · 2023: $13K · 2024: $5,831 · 2025: $5,577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,810 · Travel and Lodging: $119 · Education: $16.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16,867.30 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,809.75 |
| Travel and Lodging | $118.75 |
| Education | $16.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $46,229.95 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Otsuka America Pharmaceutical, INC. | $34,849.44 | 2019-2025 | Rexulti, Nuedexta, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $7,463.10 | 2020-2025 | Caplyta |
| Abbvie INC. | $3,450.22 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $2,674.67 | 2019-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $2,248.02 | 2019-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $1,728.73 | 2019-2022 | |
| Alkermes, INC. | $1,691.13 | 2021-2025 | Lybalvi, Aristada |
| Axsome Therapeutics, INC. | $1,544.48 | 2023-2025 | Auvelity, Sunosi |
| Janssen Pharmaceuticals, INC | $1,457.83 | 2019-2025 | Spravato |
| Supernus Pharmaceuticals, INC. | $1,071.55 | 2023-2025 | Qelbree, Qelbree |
| Allergan, INC. | $983.77 | 2019-2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $945.00 | 2019-2024 | Rexulti, Rejoyn |
| Lundbeck LLC | $726.21 | 2020-2025 | Rexulti |
| Corium, LLC | $666.27 | 2022-2024 | Azstarys |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $654.11 | 2019-2025 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $620.78 | 2024-2025 | Cobenfy |
| Jazz Pharmaceuticals INC. | $471.31 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $464.01 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $337.53 | 2022-2024 | Quviviq |
| Alfasigma USA, INC. | $329.99 | 2020-2022 | |
| Tris Pharma INC | $295.34 | 2021-2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| Ironshore Pharmaceuticals INC. | $241.96 | 2019-2020 | |
| Eisai INC. | $203.57 | 2020-2021 | |
| Shire North American Group INC | $170.96 | 2019 | |
| Bausch Health US, LLC | $100.67 | 2020-2025 | Aplenzin, Wellbutrin |
| Adlon Therapeutics L.P. | $93.27 | 2019-2021 | |
| Noven Therapeutics, LLC | $82.69 | 2024 | Xelstrym, Secuado |
| Merck Sharp & Dohme LLC | $69.38 | 2019-2022 | |
| Biodelivery Sciences International, INC. | $17.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pablo Proano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.